Adjuvant Therapy for NSCLC

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

Target Audience

This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Explain current recommendations for selecting adjuvant versus neoadjuvant therapy for patients with stage II and III non-small cell lung cancer
Additional information
Supporters: 

Supported by educational grants from:

  • Actelion
  • AstraZeneca
  • Bristol-Myers Squibb
  • BTG International
  • Celgene Corporation
  • Genentech BioOncology
  • Gilead Sciences, Medical Affairs
  • Lilly
  • Merck
  • Novartis Oncology
  • Pfizer
  • Prometheus Laboratories Inc.
  • Takeda Oncology

This activity was made possible by Pharmacyclics, Inc. and Janssen Biotech, Inc.

This activity is supported by an independent educational grant from sanofi US.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.76 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
05/08/2015
Course expires: 
03/01/2016
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 20th Annual Conference -- Lung Cancer

Gregory A. Otterson, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Available Credit

  • 0.75 Participation
  • 0.76 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing